They have no homerun drug to replace the 25 billion in revenue from keytruda.
If they can postpone the keytruda patent loss or acquire more high revenue assets things could be more optimistic. As of now A.I predicts a pipeline revenue amount of under 20 billion in revenue. Reducing revenue by close to 10 billion over the next 5 years.
HOWEVER they are aggressively acquiring and diversifying so things can quickly change.
How well do narratives help inform your perspective?
Disclaimer
The user AscendedInvestor has a position in NYSE:MRK. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
